OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Liu on the Development of Frontline Atezolizumab Combination Therapies in SCLC

November 29th 2022

Stephen V. Liu, MD, discusses efforts to develop atezolizumab-based combination therapies for patients with small cell lung cancer.

Experts Discuss Common AEs With EGFR TKIs

November 29th 2022

Zosia Piotrowska, MD, Christine Lovly, MD, PhD, and Amanda Cass, PharmD, BCPS, BCOP discuss common adverse effects with EGFR TKIs.

Experts Discuss the Risk of Skin Toxicities Associated With EGFR TKIs

November 29th 2022

Jeanne G. Vaughn, NP, Kristina Lo, PharmD, BCOP, Jonathan Riess, MD, MS, and Ticiana Leal, MD, discuss the impact of skin toxicities when utilizing EGFR TKIs.

Experts Discuss Management of Skin and Mouth TRAEs Associated With EGFR TKIs

November 28th 2022

Christine Lovly, MD, PhD, Jeanne G. Vaughn, NP, Kristina Lo, PharmD, BCOP, and Linda Ahn discuss how to approach treatment-related adverse effects of the skin and mouth associated with the use of EGFR TKIs.

Dr. Shah on Unmet Needs With CAR T-Cell Therapies in Hematologic Malignancies

November 28th 2022

Nirav N. Shah, MD, discusses remaining unmet needs with CAR T-cell therapies, and how to ameliorate these challenges for patients with hematologic malignancies.

Dr. Mascarenhas on Advancements in the Treatment Landscape of Myelofibrosis

November 28th 2022

John O. Mascarenhas, MD, discusses current advancement in the treatment landscape of myelofibrosis.

Dr. Hamilton on Trastuzumab Deruxtecan in HER2+ Breast Cancer

November 28th 2022

Erika P. Hamilton, MD, discusses previously reported and anticipated findings from the DESTINY-Breast03 trial, which compared the efficacy of 2 antibody-drug conjugates, fam-trastuzumab deruxtecan-nxki and ado-trastuzumab emtansine, in patients with HER2-positive metastatic breast cancer.

Dr. Moskowitz on Antibody-Drug Conjugates in Relapsed/Refractory DLBCL

November 28th 2022

Craig Moskowitz, MD, discusses the efficacy of several antibody-drug conjugates in diffuse large B-cell lymphoma, how their adverse effect profiles compare, and how bispecific antibodies are further defining the DLBCL treatment landscape.

Dr. Jabbour on MRD Testing in B-ALL

November 23rd 2022

Elias Jabbour, MD, discusses the importance of testing for minimal residual disease when determining optimal treatment strategies for patients with B-cell acute lymphoblastic leukemia.

Dr. Dottino on the Benefit of Early-Detection Screening in Endometrial Cancer

November 23rd 2022

Peter R. Dottino, MD, discusses the benefit of early-detection screening for endometrial cancer.

Dr. McKay on the Rationale for Triplet Frontline Therapy in RCC

November 22nd 2022

Rana R. McKay, MD, discusses the pros and cons of utilizing triplet therapy in the frontline treatment of patients with renal cell carcinoma.

Dr. Rampal on the Future Research of CDK4/6 Inhibitors in MPNs

November 22nd 2022

Raajit K. Rampal, MD, PhD, discusses the future research of CDK4/6 inhibitors in myeloproliferative neoplasms.

Dr. Jonasch on the Promise of Belzutifan in Metastatic RCC

November 22nd 2022

Eric Jonasch, MD, discusses the promise of the hypoxia inducible factor-2 alpha inhibitor belzutifan in metastatic renal cell carcinoma.

Dr. Salani on the Role of HER2 Expression in Advanced Uterine Serous Carcinoma

November 22nd 2022

Ritu Salani, MD, MBA, discusses the role of HER2 expression on treatment decisions in advanced uterine serous carcinomas.

Dr. Janakiram on Future Targets and Strategies for CAR T-cell Therapy in Myeloma

November 22nd 2022

Murali Janakiram, MD, MS, discusses future targets and research strategies for CAR T-cell therapy in multiple myeloma.

Dr. Iams on the Rationale of Targeting LAG-3 in Advanced NSCLC

November 21st 2022

Wade T. Iams, MD, discusses the rationale of targeting the LAG-3 pathway in patients with advanced non–small cell lung cancer.

Dr. Wang on the Current Treatment Options for BPDCN

November 21st 2022

Eunice Wang, MD, discusses the current treatment options for blastic plasmacytoid dendritic cell neoplasm.

Dr. Hurvitz on the Evolution of Targeted Therapies in HER2+ Breast Cancer

November 17th 2022

Sara A. Hurvitz, MD, discusses the evolution of targeted therapies in HER2-positive breast cancer.

Dr. Rampal on Pelabresib With or Without Ruxolitinib in Myelofibrosis

November 17th 2022

Raajit K. Rampal, MD, PhD, discusses the investigation of pelabresib with or without ruxolitinib in patients with myelofibrosis.

Dr. Romancik on the Benefit of Second-line Axi-cel in R/R DLBCL

November 17th 2022

Jason Romancik, MD, discusses the benefit of axicabtagene ciloleucel vs standard of care as a second-line treatment for patients with relapsed/refractory diffuse large B-cell lymphoma.